Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT05543629
Official study title

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Study summary

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986442 and Nivolumab

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 18, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?32 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Bristol-Myers Squibb
Interventions being studied
Biological: BMS-986442; Biological: Nivolumab; Drug: Docetaxel; Drug: Carboplatin; Drug: Pemexetred; Drug: Paclitaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Participants must have a life expectancy of at least 3 months at the time of first dose.
Reasons someone may not be able to joinExclusion criteria
  • Untreated symptomatic central nervous system metastases or leptomeningeal metastases.
  • Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts.
  • Participants with an active, known, or suspected autoimmune disease. Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo Clinic in Arizona - PhoenixPhoenix, Arizona
  • Local Institution - 0096Costa Mesa, California
  • Local Institution - 0075Orange, California
  • Mayo Clinic in FloridaJacksonville, Florida
  • Local Institution - 0027Orlando, Florida
  • Local Institution - 0029Fort Wayne, Indiana
  • Local Institution - 0022New Orleans, Louisiana
  • Local Institution - 0005Grand Rapids, Michigan
  • Mayo Clinic in Rochester, MinnesotaRochester, Minnesota
  • Local Institution - 0003Hackensack, New Jersey
  • Carolina BioOncology InstituteHuntersville, North Carolina
  • Local Institution - 0019Cincinnati, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 18, 2025. Always confirm current availability with the study team.

View original record ↗